Isomorphic Labs has announced a landmark $2.1 billion Series B funding round, led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. This investment significantly expands the company’s global capital base and will accelerate the scaling of its AI drug design engine, IsoDDE, while expanding its therapeutic pipeline toward clinical applications.
The funding will also support ambitious hiring targets, integrating top talent across AI, engineering, drug design, and clinical disciplines. Isomorphic Labs’ vision is to apply AI-driven breakthroughs to some of the most complex biological and medical challenges, aiming to reduce the global burden of disease. The company’s first-principles approach reimagines drug discovery as an integrated scientific and engineering discipline, with proprietary AI and data at its core.
Alphabet’s Ruth Porat praised the company’s progress, noting the profound opportunity AI offers in healthcare. Founder and CEO Sir Demis Hassabis described the funding as a massive vote of confidence in their AI-first approach, emphasizing the focus on scaling technology to deliver interventions faster. President Max Jaderberg highlighted IsoDDE’s ability to identify viable drug candidates with unprecedented speed, calling it a repeatable way to design medicines across a wide range of diseases.
The funding round also drew strong endorsements from investors. Thrive Capital’s Joshua Kushner expressed deepened conviction in Isomorphic’s mission to “solve all disease,” while GV’s Krishna Yeshwant emphasized the unmatched caliber of the team and its potential to push the boundaries of drug discovery.
Technically, Isomorphic Labs has developed proprietary AI models that form a unified drug design engine capable of working across multiple therapeutic areas and modalities. IsoDDE has demonstrated predictive accuracy bridging the gap between structure prediction and real-world drug discovery, offering a scalable foundation for AI-driven medicine. Strategic partnerships with Novartis, Lilly, and Johnson & Johnson further validate the company’s approach and highlight its growing influence in the pharmaceutical industry.
